The FDA has set a Prescription Drug User Fee Act (“PDUFA”) goal date of January 3, 2024. Food and Drug Administration (“FDA”) has accepted for filing the Biologics License Application (“BLA”) for cosibelimab, Checkpoint’s investigational anti-PD-L1 antibody, as a treatment for patients with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or radiation. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. WALTHAM, Mass., Ma(GLOBE NEWSWIRE) - Checkpoint Therapeutics, Inc. Prescription Drug User Fee Act (“PDUFA”) goal date of January 3, 2024įDA indicates that it does not currently plan to hold an advisory committee meeting
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |